Mumbai, India
Mumbai, India

Time filter

Source Type

News Article | April 27, 2017
Site: www.prnewswire.com

"Seit über zwei Jahren erweitert AEG Power Solutions kontinuierlich sein Angebot an unterbrechungsfreien Stromversorgungen für Rechenzentren und IT-Abteilungen. Unsere Systeme haben sich in den rauesten und anfoderungsreichsten industriellen Umgebungen bewährt, von Offshore-Ölplattformen bis zu Kernkraftwerken", erklärt Alessandro Nalbone, Produktmanager Data & IT UPS. "Wir können jetzt Daten- und IT-Anwendungen mit unserem Knowhow und einem umfassenden Produktportfolio an dreiphasigen USV Systemen von 10 bis 4000 kVA versorgen." Die AEG Power Solutions Gruppe ist die alleinige Tochtergesellschaft von 3W Power S.A. (WKN A114Z9 / ISINLU1072910919) mit Sitz in Luxemburg. Der Hauptsitz der Gruppe befindet sich in Zwanenburg in den Niederlanden. Die Aktien von 3W Power sind zum Handel an der Frankfurter Börse zugelassen (Tickersymbol: 3W9K).


A process for the production of pramlintide, a 37-mer peptide, is provided. The synthesis provides a high yield synthesis of the peptide in relatively pure form. Further purification can be achieved by preparative HPLC.


A low cell density fermentation process for the production of heterologous proteins in microorganisms. The cell culture obtained by cultivating host microorganisms transformed with a vector carrying genetic material for the said proteins and an inducible promoter under batch fermentation conditions is fed with a feed medium after an OD_(600 )of 0.16 to 8 has been achieved or after 0 to 4 hrs from the start of the fermentation process. The feed medium comprises 5 to 30% of carbon source and 1 to 30% of nitrogen source and 0 mg to 400 mg antibiotics and 2.5 to 4.25% inorganic phosphates and trace elements. The concentration of the carbon source in the feed medium is 10 to 30 and the amino acid content in nitrogen source is 45 to 95%. The initial feed rate is in the range of 0 ml/hr to 12 ml/hr and is raised exponentially by an exponent in the range of 0.1 to 0.4 and/or linearly with the slope of the curve in the range of 0.5 to 3. The production of the heterologous proteins is induced with 0.01-4% inducer at a cell density of OD_(600 )0.1-OD_(600 )50. The feeding of the cell culture with the feed medium and the feed rate described above is continued after production has been induced. The pO_(2 )is adjusted between 10% to 60% by passing sterile air into the fermentation broth and the temperature and pH of the fermentation broth are maintained at 33 C.-41 C. and 6.9-8.5, respectively during the entire fermentation.


Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation.


The present invention relates to an improved process for the preparation of Chlorothiazide and pharmaceutically acceptable salts thereof. The present invention relates to novel polymorphs of Chlorothiazide and Chlorothiazide salts, in particular Chlorothiazide sodium. The present invention further relates to pharmaceutical compositions comprising Chlorothiazide and Chlorothiazide salts, in particular Chlorothiazide sodium and process for preparation thereof.


Patent
USV Ltd | Date: 2011-09-09

The present invention relates to a process for preparation of Dronedarone or pharmaceutically acceptable salts thereof. More particularly, the present invention provides a process for preparation of Dronedarone hydrochloride, without the isolation of Dronedarone base.


The present invention relates to an improved process for the preparation of Rasagiline or pharmaceutically acceptable salts thereof. The present invention also relates to Rasagiline salts, polymorphs thereof and process for preparation thereof.


Patent
USV Ltd | Date: 2012-03-14

The present invention relates to a process for preparation of Dronedarone or pharmaceutically acceptable salts thereof. More particularly, the present invention provides a process for preparation of Dronedarone hydrochloride, without the isolation of Dronedarone base.


Patent
USV Ltd | Date: 2014-03-25

The present invention relates to a process for preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof. The present invention relates to novel compounds, in particular Ethyl-3-{[(2-formyl-1-methyl-1H-benzimidazole-5-yl)carobonyl]-(2-pyridinyl)amino}propanoate and Ethyl-3-{[(2-dichloromethyl-1-methyl-1H-benzimidazole-5-yl)carbonyl]-(2-pyridinyl)amino} propanoate and process for preparation thereof. The present invention further relates to the use of these novel compounds in the preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof.


The present invention relates to analytical methods such as molecular weight determination of polypeptide, in particular Glatiramer acetate. The present invention further relates to an improved process for preparation of polypeptides or pharmaceutically acceptable salts thereof, particularly Glatiramer acetate also known as Copolymer-1. The present invention further relates to characterization of Glatiramer acetate by peptide mapping.

Loading USV Ltd. collaborators
Loading USV Ltd. collaborators